MedTrace Logo

Understanding the Roles of Hormones in Adipocyte Remodeling Following Menopause

NCT03856268 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2022-11-16

No results posted yet for this study

Summary

The overarching aims of this study are to:

1. Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing surgical menopause (↓E2, ↑FSH).
2. Characterize the rate of in vivo adipogenesis, and changes in adipose tissue gene and protein expression, in the scABD and scFEM depots of women undergoing gonadal suppression (↓E2, ↓FSH).

Conditions

  • Menopause Surgical
  • Estrogen Deficiency
  • Adiposity
  • Follicle-Stimulating Hormone Deficiency
  • Hormone Deficiency

Interventions

PROCEDURE

'Surgical Menopause' Group

Women undergoing laparoscopic oophorectomy surgery ('surgical menopause') will be enrolled at Pennington Biomedical.

DRUG

'Drug-Induced Menopause' Group

Women undergoing gonadal suppression via leuprolide acetate (Lupron \[AbbVie Inc.\]) will be enrolled at the University of Colorado-Denver.

Sponsors & Collaborators

  • University of Colorado, Denver

    collaborator OTHER

  • University of Alabama at Birmingham

    collaborator OTHER

  • Pennington Biomedical Research Center

    lead OTHER

Principal Investigators

  • Kara L Marlatt, PhD, MPH · Pennington Biomedical Research Center

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2022-11-11
Completion
2022-11-11

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03856268 on ClinicalTrials.gov